



Government of Pakistan  
Ministry of National Health Services, Regulations & Coordination  
Drug Regulatory Authority Of Pakistan  
Health & OTC Products Division (Non-Drugs)  
\*\*\*\*\*

Islamabad, the 14<sup>th</sup> April, 2021

“SAY NO TO CORRUPTION”

**Subject: Submission of deficient information / documents**

The applications of following applicants were placed before the Enlistment Evaluation Committee (EEC) in its 85<sup>th</sup> meeting held on 04<sup>th</sup> February, 2021 and the same have been deferred being deficient of the information / documents as specified in column (3) of the Table below which may be furnished within 20 days of uploading of this letter on official website of DRAP along with soft data as per **Annexed Format**. Replies received after given time will not be entertained:-

S.No	Brand name	Decision
(1)	(2)	(3)
<b>M/s Biozone International, Plot No. 8, Bhengrail Road, Rawat, Islamabad (E. No. 0094)</b>		
1.	<b>IM Folic Tablets</b>	Deferred for following reason: • Strength of folic acid in calcium-LMF to be rationalized according to RDA limit.
2.	<b>Biotas Capsule</b>	Deferred till finalization of common molecules list.
<b>M/s ACE Biotics., 28-KM Multan Road, Lahore (E. No. 00852)</b>		
3.	<b>Neomen Capsule</b>	Deferred till finalization of common molecules list.
4.	<b>Osaplex Tablet</b>	Deferred till finalization of common molecules list.
5.	<b>Agiobulk Powder</b>	Deferred for submission of Monographs of active ingredients in extract form
6.	<b>Glucoflex Sachet</b>	Deferred till finalization of common molecules list.
7.	<b>Sustain Capsule</b>	Deferred for submission of Monographs of chlorophytum extract and mucuna pruriens extract
<b>M/s. Calgan Phyto Pharma (Pvt) Ltd., Plot No. 2, Green Park Road, Near Band Road Grid Station, Lahore (E. No. 00146)</b>		
8.	<b>Ovacare Tablet</b>	Deferred for following reasons: Evidence either zinc bisglycinate exists or otherwise, if former then monograph is required. Brand name needs to be changed
9.	<b>Queten Tablet</b>	Deferred for submission of signed form 3.
10.	<b>Bonbid Tablet</b>	Deferred for submission of signed form 3.
11.	<b>Optiwate Tablet</b>	Deferred for submission of signed form 3.
12.	<b>Neofol Tablet</b>	Deferred till finalization of common molecules list.
13.	<b>Trimega Drops</b>	Deferred for Clarification of “other omega 3s” being used in formulation.
<b>M/s Bio Life Enterprises Nutraceuticals, 14-KM, Adyala Road, Rawalpindi (E. No. 0061)</b>		
14.	<b>Tribestin Capsule</b>	Deferred till finalization of common molecules list.
<b>M/s MRG Laboratories (Pvt) Ltd., Plot No. C-68, S.I.T.E. Phase-I, Super Highway, Karachi-Pakistan (E. No. 00381)</b>		
15.	<b>Neurovin Syrup</b>	Deferred for submission of Monograph of ferric ammonium citrate.
<b>M/s. Arshzik (Veterinary),</b>		

S.No	Brand name	Decision
(1)	(2)	(3)
<b>23 Km Near Al-Ghani CNG, G.T. Road, Rawat, Rawalpindi (E. No. 00302)</b>		
16.	<b>Vitamono Super 1000ml Oral Liquid</b>	Deferred for clarification since duplication of product is there.
17.	<b>Hydrozik (Oral Liquid)</b>	Deferred till finalization of common molecules list.
18.	<b>Bio Gumbozol Super Oral Liquid</b>	Deferred till finalization of common molecules list.
19.	<b>Vitamino Super 1000ml Oral Liquid</b>	Deferred for clarification of following: <ul style="list-style-type: none"> <li>• Single products bears two different following brand names, needs clarification in this regard</li> <li>➤ Vitaup oral liquid</li> <li>➤ Vitamino super oral liquid</li> </ul>
20.	<b>Respofin Oral Liquid</b>	Deferred till finalization of common molecules list.
21.	<b>Herbisol Super Liquid</b>	Deferred for justification of use of glucose as an active ingredient.
22.	<b>Liso-West Powder</b>	Deferred for submission of signed form 3.
23.	<b>ND.Dot Oral Liquid</b>	Deferred for submission of signed form 3.
24.	<b>Livowest 1000ml Oral Liquid</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Signed form 3 is required.</li> <li>• silymarin is added in common molecules list.</li> </ul>
25.	<b>Bromowest Liquid</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Signed form 3 is required.</li> <li>• Ammonium chloride is added in common molecules list.</li> </ul>
26.	<b>West Gold Oral Liquid</b>	Deferred for submission of signed form 3.
27.	<b>Bcom West Oral Liquid</b>	Deferred for submission of signed form 3.
28.	<b>Vitasole-West Oral Liquid</b>	Deferred for submission of signed form 3.
29.	<b>Deka-West C Oral Liquid</b>	Deferred for submission of signed form 3 and safety profile of vitamin K3.
30.	<b>Flush-West Powder</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Signed form 3 is required.</li> <li>• Ammonium chloride is added in common molecules list.</li> </ul>
31.	<b>Gumbo-West (Oral Liquid)</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Signed form 3 is required.</li> <li>• Strength of active ingredients to be changed to weight(gram etc).</li> </ul>
32.	<b>Haydro-West (Oral Liquid)</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Strength of active ingredients to be changed to weight(gram etc).</li> </ul>
33.	<b>Mucunill (Oral Liquid)</b>	Deferred for submission of signed form 3.
34.	<b>Salmo-West Powder</b>	Deferred for submission of signed form and monographs of diatomaceous and earth yeast 60% protein.
35.	<b>Seleno-West Oral Liquid</b>	Deferred for submission of signed form 3.
36.	<b>Vita Poultry – West Oral Liquid</b>	Deferred for submission of signed form 3.
37.	<b>Electro-West Oral Liquid</b>	Deferred for submission of signed form 3.
<b>M/s Elate Pharma, Plot No. H. 165-A, S.I.T.E, Super Highway, Phase-II, Karachi (E. No. 00809)</b>		
38.	<b>Diatex-G Softgel</b>	Deferred till finalization of common molecules list.
<b>M/s ISIS Pharmaceuticals and Chemical Works (Natural Division), 25/4, Sector 12-C, North Karachi Industrial Area (E. No. 00783)</b>		
39.	<b>Iscolic Syrup</b>	Deferred for submission of prescribed signed form 3 of SRO 412(I)/2014.
40.	<b>Iscolic Drops</b>	Deferred for submission of prescribed signed form 3 of SRO 412(I)/2014.
<b>M/s Nutrabiobiotics, Nutritional Life Science, Plot No. 89-K3, Industrial Estate Hyatabad Peshawar, (E. No. 003)</b>		
41.	<b>Flexicose Tablet</b>	Deferred till finalization of common molecules list.
42.	<b>Twig-FM Capsule</b>	Deferred for following reasons: Monograph of maca root extract is required. Firm applied one product comprising of two different formulations under two different fee submissions for grant of one product enlistment, needs clarification in this regard.
43.	<b>Nutrakit-K Tablet</b>	Deferred till finalization of common molecules list.
44.	<b>Sopor M Capsule</b>	Deferred for submission of monograph of theanine.



S.No	Brand name	Decision
(1)	(2)	(3)
<b>M/s SHMZ Labs &amp; Pharmaceuticals (Pvt) Ltd., 101-Sundar Industrial Estate, Lahore (E. No. 00231)</b>		
45.	<b>SHMZ's UPCAL-D Softgel Capsule</b>	Deferred for submission of signed and stamped form 3.
46.	<b>SHMZ's Momplus Food Supplement</b>	Deferred for submission of following: Strength of all active ingredients per serving dose Either applied product is food supplement or general health product, if former then availability of food supplement section is required. Type of vitamin K being used is required.
47.	<b>SHMZ's IB SCAB Lotion</b>	Deferred till finalization of common molecules list.
48.	<b>SHMZ's Foligard Softgel Capsule</b>	Deferred for submission of signed and stamped form 3.
49.	<b>SHMZ Prolyte Sachet</b>	Deferred till finalization of common molecules list and submission of monograph of rice flour and its use as health product.
50.	<b>SHMZ's Vitalyte Sachet</b>	Deferred till finalization of common molecules list
<b>M/s Nutrimed Laboratories, Plot No. B-42, S.I.T.E. Super Highway, Karachi (E. No. 0078)</b>		
51.	<b>Sacroflor Sachet</b>	Deferred for following reasons: Monograph of saccharomyces boulardii is required. Manufacturing facility of lyophilized powder of probiotic is required.
<b>M/s Bio Life Enterprises Nutraceuticals, 14-KM, Adyala Road, Rawalpindi (E. No. 0061)</b>		
52.	<b>Biogestron Capsule</b>	Deferred for submission of monograph of soy isoflavones.
<b>M/s Medicom Superior, 122-A, Muzammal Town, Chung, Multan Road, Lahore (E. No. 00361)</b>		
53.	<b>Comtin Tablet</b>	Deferred for submission of monograph of L acetyl carnitine.
<b>M/s Novamed Healthcare (Pvt) Ltd 28-KM, Ferozepur Road, Lahore (E. No. 0018)</b>		
54.	<b>Tridiclone Gel</b>	Deferred till finalization of common molecules list.
<b>M/s Mansoor Homoeo Pahrma, LS-35, St-10/A, Block No.16, F.B. Area, Karachi (E.No. 00419)</b>		
55.	<b>Acidum Nitricum Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
56.	<b>Carduus Marianus Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
57.	<b>Chelidonium Majus Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
58.	<b>Cantharis Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> <li>• Evidence is required stating source of cantharis is not contaminated with TSE, E-coli and salmonella.</li> </ul>
59.	<b>Plantago Major Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> </ul>



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
60.	<b>Gelsenium Sempervirens Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
61.	<b>Millefolium Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
62.	<b>Carbo Vegetabilis Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
63.	<b>Thuja Occidentalis Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
64.	<b>Pulsatilla Nigricans Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
65.	<b>Colocynthis Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
66.	<b>Acidum Phosphoricum Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> <li>• Oral use of acidum phosphoricum is required.</li> </ul>
67.	<b>Arnica Montana Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
68.	<b>China Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> </ul>



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
69.	<b>Damiana Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
70.	<b>Justicia Adhatoda Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
71.	<b>Urtica Urens Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
72.	<b>Salix Nigra Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
73.	<b>Spongia Tosta Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> <li>• Evidence stating source of spongia tosta is not contaminated with TSE.</li> </ul>
74.	<b>Terminalia Arjuna Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
75.	<b>Lycopodium Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
76.	<b>Kreosotum Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> <li>• Oral safety profile of keosotum is required.</li> </ul>
77.	<b>Alfalfa Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> </ul>



S.No	Brand name	Decision
(1)	(2)	(3)
		<ul style="list-style-type: none"> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> <li>• Oral safety profile of keosotum is required.</li> </ul>
78.	<b>Cina Artemisia Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
79.	<b>Agnus Castus Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
80.	<b>Ashoka Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
81.	<b>Avena Sativa Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> <li>• Oral safety profile of keosotum is required.</li> </ul>
82.	<b>Calendula Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
83.	<b>Hamamelis Virginica Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
84.	<b>Hydrastis Canadensis Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
85.	<b>Kreosotum Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> <li>• Oral safety profile of kreosotum is required.</li> <li>• Duplication of formulation is there.</li> </ul>



S.No	Brand name	Decision
(1)	(2)	(3)
86.	<b>Teucrium Marum Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
87.	<b>Kalmegh Ø</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Availability of mother tincture section is required.</li> <li>• Strength of active ingredient per serving dose is required.</li> <li>• Prescribed signed form 3 is required.</li> <li>• Undertakings of brand name and contents of dossier are required.</li> <li>• Export order is required.</li> </ul>
<b>M/s. Focus &amp; Rulz Healthcare Division, Plot No. 44, Industrial Triangle Kahuta Road, Islamabad (E. No. 00183)</b>		
88.	<b>Menora Plus Capsule</b>	Deferred for submission of capsule (herbal) section
<b>M/s Bio Serve Pharma, Plot No. 165, 1st Floor, S.I.T.E. Super Highway, Phase-II, Karachi (Nutraceuticals) (E. No. 00466)</b>		
89.	<b>Chemagz Tablet</b>	Deferred for submission of chelated magnesium.
<b>M/s Glitz Pharma Life Care, Plot No. 265, Industrial Triangle, Kahuta Road, Islamabad (E. No. 00834)</b>		
90.	<b>MeBone Plus Tablet</b>	Deferred till finalization of common molecules list.
91.	<b>Hydralitz Plus Syrup</b>	Deferred till finalization of common molecules list.
<b>M/s Salbion Health Sciences (Pvt) Ltd., 23-Km, Sheikhpura Road, Lahore-Pakistan (E. No. 00647)</b>		
92.	<b>Thyme Oral Liquid</b>	Deferred for submission of thick thyme oil extract.
93.	<b>Rokset Capsule</b>	Deferred till finalization of common molecules list.
94.	<b>Tecas Plus Sachet</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Specific strain of each probiotic is required.</li> <li>• Characterization and testing specification of each probiotic is required.</li> <li>• Justification is required which strain of E-coli is being used as probiotic in formulation.</li> <li>• Evidence is required stating each probiotic is free from pathogenic bacteria.</li> </ul>
95.	<b>Melilora Capsule</b>	Deferred for submission of phosphotidylserine monograph..
96.	<b>Calsi Tablet</b>	Deferred for change of brand name
97.	<b>Ba – Enzime Tablet</b>	Deferred till finalization of common molecules list.
98.	<b>Flebeton Capsule</b>	Deferred for Justification is required to clarify either diosmin is used as health product or otherwise.
<b>M/s Medhouse Nutraceuticals Limited, 1-KM off, 16-KM Sargodha Road, Mangowal West, Gujrat (E. No. 00807)</b>		
99.	<b>Mega Yeast</b>	Deferred for submission of Monograph of acetyl methionine
100.	<b>Medi MilQ Plus</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Justification of use of urea as health product is required.</li> <li>• Sodium bicarbonate is added in common molecules list.</li> <li>• Safety profile of copper sulphate in high concentration is required.</li> <li>• Justification of use of rice husk as health product (for veterinary use) is required.</li> </ul>
101.	<b>Super gest</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• list.</li> <li>• Justification of use of potassium nitrate as health product is required.</li> <li>• Safety profile of copper sulphate in high concentration is required.</li> </ul>
102.	<b>Medi Colieef</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Ammonium chloride is added in common molecules list.</li> </ul>



<b>S.No</b>	<b>Brand name</b>	<b>Decision</b>
<b>(1)</b>	<b>(2)</b>	<b>(3)</b>
		<ul style="list-style-type: none"><li>• Justification of use of rose petal dry is required.</li><li>• Justification of use of potassium nitrate as health product is required.</li><li>• Justification of use of camphor for oral intake (for veterinary use) is required.</li></ul>
103.	<b>Farma Yeast</b>	Deferred for following reasons: <ul style="list-style-type: none"><li>• Monograph of acetyl methionine is required.</li><li>• Yeast is considered as probiotic hence availability of probiotic section is required.</li><li>• Testing specification of yeast is required.</li></ul>
104.	<b>Medi Gest</b>	Deferred for following reasons: <ul style="list-style-type: none"><li>• Sodium bicarbonate and Ammonium chloride is added in common molecules list.</li><li>• Justification of use of potassium nitrate as health product is required.</li><li>• Safety profile of copper sulphate in high concentration is required.</li></ul>
105.	<b>Medi Liv Plus</b>	Deferred for submission of monograph of acetyl methionine.

  
(Ayyaz Ahmad)

**Secretary, Enlistment Evaluation Committee**



# ANNEXURE

The firm is directed to submit soft data in both MS Excel & MS Word on following formats in **USB ONLY.**

## MS Excel Format

Sr. No.	Company name	Product Name	Dosage Form	Composition	Common name	Recommended use	Pack Size	Date of R&I submission
1.	(Company name, City)  Without address	XYZ	Tablet	Each tablet contains:  Abc (USP)...50mg	XXX	XXX	10's 20's	DD.MM.YYYY
2.								

## MS Word Format

Sr. No.	Company name	Product Name and composition	Common name	Recommended use	Pack Size
1.	(Company name, City)  Without address	XYZ Tablet  Each tablet contains: Abc (USP)...50mg	XXX	XXX	10's 20's
2.					